Dow Up0.08% Nasdaq Down0.30%

TapImmune, Inc. (TPIV)

-Other OTC
0.98 Up 0.01(0.52%) Sep 19, 3:50PM EDT
ProfileGet Profile for:
TapImmune, Inc.
1551 Eastlake Avenue East
Suite 100
Seattle, WA 98102
United States - Map
Phone: 206-504-7278
Website: http://www.tapimmune.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:2

Business Summary 

TapImmune Inc., clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases. It is involved in the development of HER2/neu, a vaccine technology, which is in Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which is in Phase I human clinical trials for the treatment of breast and ovarian cancer. The company’s products under preclinical stage include Polystart, a nucleic acid–based technology for Her2/neu breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. TapImmune Inc. has a technology option agreement with Mayo Foundation for the evaluation of HER2/neu peptide epitopes, as well as has a research license and option agreement with Crucell Holland B.V. The company was founded in 1999 and is based in Seattle, Washington.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on TapImmune, Inc.

Key Executives 
 PayExercised
Mr. Glynn Wilson Ph.D., 67
Exec. Chairman, Chief Exec. Officer, Pres, Acting Principal Accounting Officer, Member of Audit Committee and Member of Compensation Committee
180.00K0.00
Mr. Mark A. Reddish BOD, 59
VP of Devel. and Member of Audit Committee
60.00K0.00
Venissa Izaguirre ,
Operations Mang.
N/AN/A
Dr. Robert Florkiewicz Ph.D.,
Sr. Director of Molecular Biology & Virology
N/AN/A
Mr. Sailesh C. Barchha ,
Advisor to Board
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders